Quelles thérapeutiques proposer dans la maladie de Parkinson du sujet âgé ?

Springer Science and Business Media LLC - Tập 4 Số 2 - Trang 50-55 - 2012
Emmanuel Roze1
1Département de neurologie, Hôpital Salpêtrière, 47-83 boulevard de l’hôpital, F-75651, Paris cedex 13, France

Tóm tắt

Từ khóa


Tài liệu tham khảo

Muangpaisan W, Mathews A, Hori H, Seidel D (2011) A systematic review of the worldwide prevalence and incidence of Parkinson’s disease. J Med Assoc Thai 94:749–755

Dowding CH, Shenton CL, Salek SS (2006) A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 23:693–721

Chen JJ (2010) Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 16 Suppl Implications:S87–S93

Kaltenboeck A, Johnson SJ, Davis MR, et al (2011) Direct costs and survival of medicare beneficiaries with early and advanced parkinson’s disease. Parkinsonism Relat Disord [Epub ahead of print]

Gage H, Hendricks A, Zhang S, Kazis L (2003) The relative health related quality of life of veterans with Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:163–169

Soh SE, Morris ME, McGinley JL (2011) Determinants of healthrelated quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 17:1–9

Conférence de consensus (2000) Maladie de Parkinson: diagnostic et traitement. Rev Neurol (Paris) 156Suppl 2 Pt 2:281–294

Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidencebased medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 20:523–539

Fox SH, Katzenschlager R, Lim SY, et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26Suppl 3:S2–S41

Seppi K, Weintraub D, Coelho M, et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26 Suppl 3:S42–S80

Jego M, Viallet F (2009) Maladie de Parkinson du sujet âgé: prise en carge thérapeutique: médicaments à prescrire, médicaments à éviter. Rev Geriatr 34:8–11

Geny C (2009) Spécificités gériatriques de la maladie de Parkinson. Rev Geriatr 34:4–7

Petit H, Vermersch P, Pasquier F (1992) Some clinical aspects of late onset parkinsonism. Clin Neurol Neurosurg 94Suppl: S137–S138

Diederich NJ, Moore CG, Leurgans SE, et al (2003) Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 60:529–533

Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 19:1043–1049

Friedman A (1994) Old-onset Parkinson’s disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 89:258–261

Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology 38:1402–1406

Bainbridge JL, Ruscin JM (2009) Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging 26:145–155

Grosset D, Antonini A, Canesi M, et al (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord 24:826–832

Lauretani F, Maggio M, Silvestrini C, et al (2012) Parkinson’s disease (PD) in the elderly: an example of geriatric syndrome (GS)? Arch Gerontol Geriatr 54:242–246

Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a populationbased, prospective study. J Am Geriatr Soc 48:938–942

Leopold NA, Polansky M, Hurka MR (2004) Drug adherence in Parkinson’s disease. Mov Disord 19:513–517

Peterson AM, Takiya L, Finley R (2003) Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 60:657–665

Schlenk EA, Bernardo LM, Organist LA, et al (2008) Optimizing Medication Adherence in Older Patients: A Systematic Review. J Clin Outcomes Manag 15:595–606

Marciniak CM, Choo CM, Toledo SD, et al (2011) Do comorbidities and cognition impact functional change and discharge needs in Parkinson disease? Am J Phys Med Rehabil 90:272–280

Goy ER, Carter JH, Ganzini L (2008) Needs and experiences of caregivers for family members dying with Parkinson disease. J Palliat Care 24:69–75

Lanoix M (2009) Palliative care and Parkinson’s disease: managing the chronic-palliative interface. Chronic Illn 5:46–55

Lokk J (2011) Parkinson’s disease permanent care unit: managing the chronic-palliative interface. J Multidiscip Healthc 4:33–38

Rascol O, Brooks DJ, Melamed E, et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947–954

Pellicano C, Benincasa D, Giovannelli M, et al (2009) Entacapone in elderly Parkinsonian patients experiencing levodoparelated wearing-off: a pilot study. Neurol Res 31:74–76

Goetz CG, Schwid SR, Eberly SW, et al (2006) Safety of rasagiline in elderly patients with Parkinson disease. Neurology 66:1427–1429

Tolosa E, Stern MB (2011) Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. Eur J Neurol 19:258–264

Chen JJ, Fernandez HH (2007) Community and long-term care management of Parkinson’s disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs Aging 24:663–680

Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 23:1130–1136

Devos D (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000

Shulman LM, Minagar A, Rabinstein A, Weiner WJ (2000) The use of dopamine agonists in very elderly patients with Parkinson’s disease. Mov Disord 15:664–668

Derost PP, Ouchchane L, Morand D, et al (2007) Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 68:1345–1355

Vesper J, Haak S, Ostertag C, Nikkhah G (2007) Subthalamic nucleus deep brain stimulation in elderly patients—analysis of outcome and complications. BMC Neurol 7:7

Rouaud T, Dondaine T, Drapier S, et al (2010) Pallidal stimulation in advanced Parkinson’s patients with contraindications for subthalamic stimulation. Mov Disord 25:1839–1846

Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al (2010) The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:704–709

Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR (2011) The impact of non-motor symptoms on healthrelated quality of life of patients with Parkinson’s disease. Mov Disord 26:399–406

Margis R, Donis KC, Schonwald SV, Rieder CR (2010) WHOQOL-OLD assessment of quality of life in elderly patients with Parkinson’s disease: influence of sleep and depressive symptoms. Rev Bras Psiquiatr 32:125–131

Reichmann H, Schneider C, Lohle M (2009) Non-motor features of Parkinson’s disease: depression and dementia. Parkinsonism Relat Disord 15 Suppl 3:S87–S92

Winter Y, von Campenhausen S, Arend M, et al (2011) Healthrelated quality of life and its determinants in Parkinson’s disease: results of an Italian cohort study. Parkinsonism Relat Disord 17:265–269

Truong DD, Bhidayasiri R, Wolters E (2008) Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 266:216–228

Zesiewicz TA, Sullivan KL, Arnulf I, et al (2010) Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74:924–931

O’Connor DW, Sierakowski C, Chin LF, Singh D (2010) The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J Biol Psychiatry 11:788–791